MedTrace Logo

A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

NCT01004016 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2010-09-28

No results posted yet for this study

Summary

To evaluate the efficacy and safety of KPS-0373 in patients with SCD.

Conditions

  • Spinocerebellar Degeneration

Interventions

DRUG

KPS-0373

DRUG

Placebo

Sponsors & Collaborators

  • Kissei Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yasuhiro Omori · Clinical Development Department, Kissei Pharmaceutical Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Japan

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01004016 on ClinicalTrials.gov